Endocrine Abstracts (2019) 65 P212 | DOI: 10.1530/endoabs.65.P212

An audit of SGLT2-inhibitors in the management of type 2 diabetes in Sligo University Hospital Ireland: metabolic and haemodynamic outcomes

Avinash Radhakrishna & Catherine Mchugh

Sligo University Hospital, Sligo, Ireland

Introduction: Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors are the latest class of anti-hyperglycaemic agents which reduce blood glucose by increasing urinary glucose excretion.

Aims: 1) To assess the metabolic and haemodynamic changes associated with SGLT-2 inhibitors in patients attending Sligo University Hospital (SUH) Ireland.

2) To enhance prescriber awareness across disciplines regarding the metabolic and haemodynamic benefits in addition to improving cardio-renal outcomes as demonstrated in the EMPAREG, CANVAS & DECLARE meta-analysis

Methodology: After screening for eligibility, we selected 98 patients prescribed SGLT2-Inhibitors between January 2014 to December 2018. We excluded those with incomplete data and whose medications were stopped during the initial 6-month period. Retrospective data was collected from Medical Charts, NIMIS®, IPMS® and ProWellness IT Diabetes Database®. Data was collected at Baseline and at 6 months after the start of SGLT-2i for body weight, blood pressure, HbA1c and lipid profile.

Mean HbA1c was 8.89(1.44) % at baseline which dropped significantly to 8.04(1.22) % at 6 months. A similar highly significant change was observed when comparing weights at baseline and 6 months: 95.49(20.5) kg to 93.29(19.6)kg. Blood pressure changes were remarkable but there was only a modest improvement of HDL with no significant changes in Total Cholesterol, LDL and Triglycerides.


Baseline Characteristics (n=98)
Age (Years)62.13 ± (12.29)
DM Duration (Years)1–29
Median Treatment (Years)2
Sex (Male/Female)61/37
Changes in The Examined Variables After 6 Months Of Starting SGLT2-Inhibitors
Pre-Treatment6 MonthsP
HbA1c (%)8.808.04<0.0001
Systolic Blood Pressure (mmHg)143.75135.41<0.0001
Diastolic Blood Pressure (mmHg)80.6077.96<0.0001
Weight (kg)95.4993.29<0.0001
HDL-C (mmol/l)1.1541.0950.004

Conclusion: The use of SGLT-2 Inhibitors in SUH was associated with significant metabolic and haemodynamic improvements which were better than expected when compared with those documented in large volume trials

Article tools

My recent searches

No recent searches.